“The vaccine was administered to two recruits at the preventive and therapeutic clinical trial unit (PTCTU) in the hospital, the only institute in Odisha chosen by the Indian Council for Medical Research (ICMR) for the human trial of the vaccine,” said E Venkata Rao, the principal investigator of the Covaxin human trial.
The trial of this indigenous vaccine, being developed by Bharat Biotech and the ICMR, is being conducted at 21 selected medical institutes across the country.
“This Phase-3 trial will check the efficacy of the vaccine. It will evaluate if the vaccine was actually able to prevent the disease among the recipients of the vaccine,” he said, adding, “Safety check (Phase 1) primarily looked at its safety aspect for human use without any significant side effect.”
During this trial, two doses will be administered to each volunteer 28 days apart but the follow-up period will extend to 12 months to understand its long-term and side effects.
“Covaxin was an inactivated whole cell virion without the ability to produce the disease but helped in developing antibodies against the infection. These are time-tested vaccines while the others being developed were mRNA vaccines, new to human population, which send a signal into the human cell for the production of antibodies against the disease,” said Rao.
Volunteers desirous of participating in the Covaxin trial could register online on the portal http://ptctu.soa.ac.in or can send a message through WhatsApp with their name, age, gender and the place of residence to 7849021450, an official source said.